STAT3 and neuroblastoma: Preclinical studies with AZD9150 in lymphoma (KARPAS299 and SUP-M2) [63] and neuroblastoma (IMR 32) [64] cell lines with aberrantly activated STAT3 showed a decrease in the expression of STAT3 protein and downstream signaling targets.